Na Li

Na Li

Auto-generated profile, based on publicly available information

Na Li

School of Life Sciences, Liaoning Provincial Key Laboratory of Biotechnology and Drug Discovery, Liaoning Normal University, Dalian, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
NLNa Li
Na Li
MLMichael A. Lopez
Michael A. Lopez
MLMaría Linares
María Linares
SKSubodh Kumar
Subodh Kumar
SOStefania Oliva
Stefania Oliva
MFMariateresa Fulciniti
Mariateresa Fulciniti
Purpose: p21-activated kinase 4 (PAK4) plays a significant biological and functional role in a number of malignancies, including multiple myeloma (MM). On the basis of our promising findings in MM, we here characterize PAK4 expression and role in WM cells, as well effect of dual PAK4-NAMPT inhibitor (KPT-9274) against WM cell growth and viability. Experimental Design: We have analyzed mRNA and protein expression levels of PAK4 in WM cells, and used loss-of-function approach to investigate its contribution to WM cell viability. We have further tested the in vitro and in vivo effect of KPT-9274 against WM cell growth and viability. Results: We report here high-level expression and functional role of PAK4 in WM, as demonstrated by shRNA-mediated knockdown; and significant impact of KPT-9274 on WM cell growth and viability. The growth inhibitory effect of KPT-9274 was associated with decreased PAK4 expression and NAMPT activity, as well as induction of apoptosis. Interestingly, in WM cell lines treated with KPT-9274, we detected a significant impact on DNA damage and repair genes. Moreover, we observed that apart from inducing DNA damage, KPT-9274 specifically decreased RAD51 and the double-strand break repair by the homologous recombination pathway. As a result, when combined with a DNA alkylating agents bendamustine and melphalan, KPT-9274 provided a synergistic inhibition of cell viability in WM cell lines and primary patient WM cells in vitro and in vivo. Conclusions: These results support the clinical investigation of KPT-9274 in combination with DNA-damaging agent for treatment of WM.

27 February 2026 in Blood Advances
Verified
Journal Article
Open access
NLNa Li
Na Li
YLYicen Liu
Yicen Liu
LZLinna Zhang
Linna Zhang
SGSaisai Guo
Saisai Guo
ZWZhihao Wu
Zhihao Wu
HYHong Yang
Hong Yang
Patients with TP53 mutant mantle cell lymphoma (MCL) face poor chemotherapy response and early progression, requiring novel therapies. Nicotinamide phosphoribosyl transferase (NAMPT), the rate-limiting nicotinamide adenine dinucleotide salvage enzyme overexpressed in MCL cell lines and patient tissues, emerges as a therapeutic target. The NAMPT inhibitor KPT-9274 reduced viability and induced apoptosis in MCL cells irrespective of TP53 status. Mechanistic studies reveal a striking dichotomy: in TP53 mutant cells, NAMPT inhibition triggers synthetic lethality through catastrophic DNA damage response (DDR) pathway disruption, whereas in TP53 wild-type cells, it selectively suppresses B-cell receptor (BCR) signaling and immune checkpoint activation. This biological divergence translates to clinically actionable synergies: TP53 mutant cells exhibit marked sensitization to alkylating agents and DDR-targeting therapies, whereas TP53 wild-type models show potential for overcoming BTK inhibitor resistance. In vivo studies confirm that NAMPT-based combinations achieve profound tumor regression in TP53 mutant xenografts without exacerbating toxicity. Our findings establish NAMPT as a dual-context therapeutic node, providing a precision medicine framework to circumvent chemoresistance in high-risk MCL. These results advocate for the clinical evaluation of TP53 status–guided NAMPT inhibitor combinations to address this unmet oncologic challenge.